What is the maximum dose of tirzepatide for weight loss?

Why does tirzepatide have a maximum dose at all?

Every medicine has a ceiling beyond which the added benefit stops outweighing the added risk. For tirzepatide, the clinical programme tested doses up to 15 mg and found that weight loss continued to increase with each step up through the schedule. The MHRA therefore licensed 15 mg as the highest approved dose for weight management in the UK, reflecting the evidence base that existed at approval. Going above it would be outside the licensed indication, unsupported by safety data, and something no GPhC-registered prescriber should do.

It is also worth understanding what 15 mg actually represents in the titration. The six UK strengths (2.5, 5, 7.5, 10, 12.5 and 15 mg) are not discrete medicines but steps in a single escalating schedule. Your body's tolerance at each rung shapes whether you move up, hold steady, or, occasionally, step back down. The prescriber's judgement is the mechanism, not a fixed calendar.

The Mounjaro treatment overview explains how tirzepatide works as a dual GIP and GLP-1 receptor agonist, which is the pharmacological reason its effects on appetite and satiety strengthen as the dose increases.

What does the trial evidence show at the highest dose?

The clearest picture comes from SURMOUNT-1, a 72-week study published in the New England Journal of Medicine, which enrolled 2,539 adults with obesity or overweight and at least one weight-related condition. Participants on 15 mg achieved an average body-weight reduction of around 20–21%, with some analyses reporting up to approximately 22.5% in specific subgroups. Those are trial averages across thousands of adults following a defined protocol alongside a reduced-calorie diet and increased activity, real-world results will vary, and a prescriber will always frame expectations honestly.

NICE reviewed this evidence in its technology appraisal of tirzepatide (TA1026, published December 2024) and concluded the medicine is recommended within its licensed population. The committee noted that the weight-loss results across the SURMOUNT programme were clinically meaningful, particularly at the higher doses. If someone achieves less than 5% weight loss after six months at the highest dose they have tolerated, the appraisal guidance suggests reviewing whether continuing is appropriate, a sensible clinical checkpoint, not a failure.

For a direct look at what the earlier steps deliver, the 5 mg evidence page sets out what participants typically saw before reaching the upper part of the schedule.

Does reaching 15 mg guarantee the best outcome?

Not automatically, and this is a question our prescribers hear regularly. Clinical trials show a dose-response relationship (on average, higher doses produced greater weight loss) but the word "average" matters. Some people respond very well at 10 mg; others need the full 15 mg to see the same result. Biology, individual tolerability, metabolic factors and how closely the lifestyle changes are followed all affect the outcome alongside the dose number.

There is also a practical point about tolerability. Gastrointestinal side effects (nausea, loose stools, indigestion) are most likely to appear after starting treatment or after a dose increase, and they tend to settle within days to two weeks as your system adapts. Rushing the titration to reach 15 mg faster does not serve most people; the graduated schedule exists because it produces better long-term adherence. The NHS guidance on tirzepatide explains this clearly in the patient-facing information.

If you are mid-treatment and wondering how your current dose compares to the maximum, the 7.5 mg page covers what the mid-schedule evidence looks like, which can help put your own progress in context.

Who can reach the maximum dose through a private prescription?

Any adult who meets the licensed eligibility criteria for tirzepatide (broadly, a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, dyslipidaemia or type 2 diabetes) can be assessed for private treatment. Ethnic-background adjustments to those thresholds apply under UK guidance. Reaching 15 mg specifically is a matter of titrating through the schedule under clinical supervision, not of meeting a different eligibility bar.

What a prescriber cannot do is commit in advance that you will reach any particular dose. Each step requires a clinical review. At nume, that review happens before every repeat order, a real prescriber, not an automated system, looks at how things are going for you. Orders placed by noon on a working day are dispatched the same day once approved, and the pen arrives free the next working day via DPD in plain, unbranded packaging. That kind of oversight is exactly what dose titration requires.

Cost is a fair consideration when you are looking at treatment that may run across multiple months and doses. The Mounjaro pricing page sets out what private tirzepatide treatment typically costs in the UK and what a legitimate price includes, worth reading before comparing numbers from different providers.

If you are ready to explore whether tirzepatide is clinically suitable for you, beginning with an understanding of how the 2.5 mg starting dose works for weight loss is a good first step before speaking to our prescribers through a free consultation, same-day clinical review, no waiting list.